8-K: Metsera's Obesity Drug MET-233i Shows Promising Phase 1 Results with Significant Weight Loss and Favorable Tolerability

Metsera, Inc. announced positive topline results from its Phase 1 clinical trial of MET-233i, an ultra-long acting amylin analog for obesity, demonstrating dose-dependent weight loss and general tolerability.

Summary

• Metsera, Inc. reported positive topline results from its Phase 1 clinical trial for MET-233i, an investigational subcutaneously injectable ultra-long acting amylin analog for obesity and overweight.
• The trial included a Single Ascending Dose (SAD) portion with 40 participants across five cohorts and a Multiple Ascending Dose (MAD) portion with 40 participants across four cohorts.
• In the SAD portion, a mean placebo-subtracted weight loss of 5.3% was observed at day 8 for the 2.4 mg dose, with placebo showing a 0.9% change from baseline.
• In the MAD portion, participants receiving five weekly doses of MET-233i showed a mean placebo-subtracted weight loss of 8.4% at day 36 for the 1.2 mg dose, compared to a 0.6% placebo change.
• MET-233i was generally well-tolerated in both SAD and MAD portions, with most frequent adverse events being mild, dose-dependent gastrointestinal issues like nausea and vomiting.
• In the MAD portion, gastrointestinal-related adverse events were mostly confined to the first week, and only 3 out of 40 participants (7.5%) discontinued, none due to adverse events.
• Pharmacokinetic analysis showed a half-life of approximately 19 days for MET-233i in the SAD portion, indicating its ultra-long acting profile.
• The company plans to advance MET-233i as a monotherapy and in combination with MET-097i, with further trial data expected in late 2025 and early 2026.

Sentiment

Score: 8

Explanation: The document reports positive topline Phase 1 clinical trial results for MET-233i, showing significant dose-dependent weight loss and general tolerability with mostly mild and manageable side effects. The ultra-long acting profile and potential for monthly dosing are strong positives. While GI side effects are noted, their mildness and transient nature are favorable. The outlook for advancing the drug and upcoming data releases is also positive.

Positives

• MET-233i demonstrated dose-dependent weight loss in both single and multiple ascending dose portions of the Phase 1 trial.
• A significant mean placebo-subtracted weight loss of 5.3% was achieved at day 8 with a single 2.4 mg dose.
• A substantial mean placebo-subtracted weight loss of 8.4% was observed at day 36 with weekly 1.2 mg doses.
• The drug was generally well-tolerated across all cohorts in both SAD and MAD studies.
• Most treatment-emergent adverse events (TEAEs) were mild, particularly in the MAD portion where all GI-related TEAEs were mild.
• Gastrointestinal TEAEs were largely confined to the first week of treatment in the MAD portion, despite increasing drug exposure.
• Only 7.5% of participants discontinued the MAD trial, and none of these discontinuations were attributed to TEAEs.
• The observed half-life of approximately 19 days supports MET-233i's ultra-long acting profile.
• PK analysis consistency with MET-097i supports the potential for a monthly multi-nutrient stimulated hormone combination.

Negatives

• Gastrointestinal-related treatment-emergent adverse events (TEAEs), primarily nausea and vomiting, were the most frequent and dose-dependent.
• In the SAD portion, 100% of participants in the 2.4 mg dose cohort experienced at least one GI AE and nausea, with 83.3% experiencing vomiting.
• In the MAD portion, 100% of participants in the 1.2 mg dose cohort experienced at least one GI AE and nausea, and 37.5% experienced vomiting.

Risks

• The company has a limited operating history, which may impact its ability to generate revenue or become profitable.
• There is a risk of failure to obtain additional capital when needed on acceptable terms or at all, which could lead to dilution for stockholders or require relinquishing rights to technologies or product candidates.
• The company's success is highly dependent on the successful development and approval of its product candidates.
• Risks are associated with preclinical and clinical development, including difficulties or delays in trial commencement, completion, termination, or suspension.
• The company may face challenges in timely enrolling participants in its clinical trials.
• Current or future product candidates may be associated with side effects, adverse events, or other safety risks.
• Risks are associated with the regulatory approval processes of the FDA and comparable foreign authorities.
• Conducting clinical trials and preclinical studies outside of the United States presents additional risks.
• The company relies on third parties to conduct clinical trials and preclinical studies, as well as for the manufacture and shipping of its product candidates.
• Risks are associated with existing license and collaboration agreements and future strategic alliances.
• The industry is highly competitive, and product candidates intended for biologic approval may face competition sooner than anticipated.
• The company's success is dependent on its ability to attract and retain highly qualified management and other clinical and scientific personnel.
• There is a risk that the company or its licensors may be unable to obtain, maintain, defend, and enforce patent or other intellectual property protection for its current or future product candidates or technology.
• Risks are associated with the company's common stock, as detailed in its SEC filings.

Future Outlook

Metsera is advancing MET-233i as a potential monotherapy and in combination with MET-097i, based on the positive Phase 1 data. Topline data from an ongoing monotherapy trial evaluating 12 weekly doses followed by a monthly dose is expected in late 2025. The company has extended an ongoing co-administration trial of MET-233i and MET-097i to twelve weeks, with topline data anticipated by year-end 2025 or early 2026. Additionally, topline clinical data for its ultra-long acting glucose-dependent insulinotropic polypeptide receptor agonist, MET-034i, in combination with MET-097i, is expected in late 2025.

Management Comments

• The Company believes the positive data from the Phase 1 trial supports advancing MET-233i as a potential monotherapy and in combination with MET-097i.
• The consistency of MET-233i's PK analysis with MET-097i supports the potential for a monthly multi-nutrient stimulated hormone combination.

Industry Context

The announcement positions Metsera as a contender in the rapidly evolving obesity treatment market, which is seeing significant innovation with new classes of drugs like GLP-1 and amylin analogs. The development of an ultra-long acting amylin analog like MET-233i, especially with a potential monthly dosing regimen, could offer a competitive advantage by improving patient adherence and convenience compared to existing weekly or daily injectables. The exploration of combination therapies, such as with MET-097i, aligns with the industry trend towards multi-modal approaches to achieve greater efficacy in weight management.

Stakeholder Impact

• **Shareholders**: Positive clinical trial results are likely to increase investor confidence and potentially lead to an increase in share price. However, the mention of potential future capital raises and associated dilution risks could be a concern.
• **Patients (Obesity/Overweight)**: The positive Phase 1 results suggest a promising new treatment option, especially given its ultra-long acting nature and potential for monthly dosing, which could improve adherence and quality of life.
• **Employees**: Positive trial results and advancement of the pipeline could lead to increased job security and potential growth opportunities within the company.
• **Competitors**: The development of a new, potentially differentiated obesity treatment could increase competitive pressure in the market.

Next Steps

• Advance MET-233i as a potential monotherapy.
• Advance MET-233i in combination with MET-097i.
• Report topline data from an ongoing monotherapy trial of MET-233i (12 weekly doses with titration, followed by monthly dose) in late 2025.
• Report topline data from an extended co-administration trial of MET-233i and MET-097i (12 weeks) by year-end 2025 or early 2026.
• Report topline clinical data from MET-034i (ultra-long acting glucose-dependent insulinotropic polypeptide receptor agonist) in combination with MET-097i in late 2025.

Key Dates

Recommendation

Keywords

Metsera, MET-233i, obesity treatment, overweight, Phase 1 clinical trial, amylin analog, weight loss, pharmacokinetics, clinical development, biotechnology, pharmaceuticals, drug development, amylin, GIP receptor agonist, MET-097i, MET-034i